Clinical trial Recruiting at 1 site Observational Ages 18 and up

Using retinal markers to predict disease progression in neuroinflammatory diseases

Official title: Retinal Markers in Neuroinflammatory Diseases: a Prospective Observational Study

Run by University Hospital, Basel, Switzerland · NCT06369766 · Data updated 2026-11-12

This study is testing if eye exams can help predict how Multiple Sclerosis and other neuroinflammatory diseases will progress in patients.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment500 (estimated)
SponsorUniversity Hospital, Basel, Switzerland
Academic / other
Locations1 site (Basel)
StatusRecruiting
StartedJanuary 31, 2024
Main results expectedDecember 2028
Study endsFebruary 2029
Registry record updatedMay 23, 2025
Trial IDNCT06369766 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults over 18 years old diagnosed with Multiple Sclerosis or other neuroinflammatory diseases.

Probably not a fit

Patients with significant ocular pathology or those unable to undergo Optical Coherence Tomography (OCT) may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the predictive value of retinal markers in patients with Multiple Sclerosis and other neuroinflammatory diseases, as well as healthy controls. Participants will undergo non-invasive retinal examinations and complete a questionnaire to assess various retinal measures. The focus is on identifying neuroaxonal loss and neuroinflammation in the retina, which may indicate progression independent of relapse activity (PIRA). The study seeks to improve early identification of patients at risk for PIRA, which is crucial for effective management of Multiple Sclerosis.

Why it matters

Potential benefit: If successful, this study could lead to improved early detection of disease progression in patients with neuroinflammatory diseases, allowing for better therapeutic decisions.

How similar studies have gone: While the use of retinal markers in this context is promising, the specific predictive value for PIRA in neuroinflammatory diseases is still being explored and may represent a novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. All groups:

   * Age \>18 years old
2. Patients with Multiple Sclerosis:

   * Diagnosis of Multiple Sclerosis, according to the last revisions of the McDonald Criteria (2017)
3. Patients with other neuroinflammatory diseases:

   * Diagnosis of Neuromyelitis optica spectrum disorder or Myelin oligodendrocyte glycoprotein antibody disease or other neuroinflammatory disorders other than Multiple Sclerosis

Exclusion Criteria:

1. All groups:

   * Inability to undergo Optical Coherence Tomography (OCT) and/or retinal vessel imaging (e.g. severe nystagmus that prevents eye fixation on both eyes)
   * Presence of any ocular pathology that may interfere with the validity of the OCT/retinal vessel analysis (cataracts, glaucoma, history of refractive defects \>6 D etc.).
   * Pregnancy and Lactation
2. Healthy Controls

   * History of other neurological conditions: participants with a history of other significant neurological conditions that might interfere with the assessment or interpretation of the signs and symptoms will be excluded (e.g. confirmed Stroke, Acute disseminated encephalomyelitis, Chronic inflammatory Demyelinating Disease, Polyneuropathy, etc.)

Where it's running

  • University Hospital Basel, Department of Neurology
    Basel, Switzerland
    Recruiting

Study contacts

  • Principal investigator: Athina Papadopoulou, PD Dr. med. — University Hospital Basel, Department of Neurology
  • Study coordinator: Athina Papadopoulou, PD Dr. med.
  • Email: Athina.Papadopoulou@usb.ch
  • Phone: +41 61 32 85704

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.